IF YOU HAVE PREVIOUSLY REGISTERED FOR THIS EVENT, PLEASE LOG IN BELOW OR CLICK THE LINK ON THE EMAIL YOU RECEIVED:

REDEFINING SURVIVAL EXPECTATIONS IN LUNG CANCER


Federico Cappuzzo

Federico Cappuzzo

Director of Hematology and Oncology Department AUSL Romagna-Ravenna
Ravenna, Italy

Dr. Federico Cappuzzo has been the Director of Medical Oncology at AUSL della Romagna-Ravenna since April 2016 and since January 2017 is the Director on Hematology and Oncology Department. In November 1992, he graduated, summa cum laude, in Medicine and surgery at the Palermo University and in November 1996, yielded a Degree summa cum laude in Medical Oncology at Milan University, followed by the ESMO (European Society for Medical Oncology) certification in Medical Oncology in 1997. From 1997 to 1999 he was recipient of an ESMO Fellowship on Gene Therapy of Lung Cancer at Institut Gustave Roussy in Villejuif (Paris). Followed by attendance from April 2000 to September 2000 at the thoracic oncology unit at Medical University of South Carolina in Charleston (USA). For six years, from November 2000 to 2006, he was assistant professor at Ospedale Bellaria in Bologna and from November 2006 to January 2010 he was assistant professor in Medical Oncology at Istituto Clinico Humanitas IRCCS in Rozzano (Milano), which was followed in January 2004 to November 2004 as visiting associate professor in Medical Oncology at University of Colorado in Denver (USA). From January 2010 to April 2016 he was the Director of Medical Oncology Department at the Istituto Toscano Tumori-Ospedale Civile in Livorno. Dr. Cappuzzo is a member of the Italian Association in Medical Oncology (AIOM), European Society for Medical Oncology (ESMO), American Society Clinical Oncology (ASCO) and International Association for the Study of Lung Cancer (IASCL) and since 2006 as a Member of the editorial board of Lung Cancer. From January 2016 he is the Chairman of the Educational Committee of IASLC. In 2006, 2009 and 2012 he received research grants from the Italian Association for Cancer Research (AIRC) on targeted therapies in lung cancer and is the author of more than 200 papers in peer-review journals, mainly in translational research in lung cancer.

Roy Herbst 

Roy Herbst 

Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Associate Director for Translational  Research, Yale Comprehensive Cancer Center Yale School of Medicine, New Haven, CT, USA 

Dr. Roy Herbst is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research at Yale Cancer Center (YCC) and Yale School of Medicine, New Haven, CT. Dr. Herbst has worked over several decades as a pioneer of personalized medicine and immunotherapy to identify biomarkers and bring novel targeted treatments and immunotherapies to patients, serving as principal investigator for numerous clinical trials testing these agents in advanced stage lung cancers. This work led to the approval of several therapies (such as Gefitinib, Cetuximab, Bevacizumab, Axitinib, Atezolizumab, and Pembrolizumab), which have revolutionized the field and greatly enhanced patient survival. His work on "umbrella” trials has galvanized the field of targeted therapy and cancer drug approvals at the FDA. Nationally, he is at the forefront of personalized medicine and works closely with public-private partnerships to develop large clinical studies, such as Lung-MAP. He testified on this before the House of Representatives 21st Century Cures committee and served as a prominent figure in this area as a member of the NAM Policy forum for 9 years. The NCI Lung SPORE he leads has identified new mechanisms of sensitivity and resistance to immunotherapy. Dr. Herbst is a highly respected clinician­ scientist who has been a champion of translational medicine for decades, recently authoring a high-profile review of the 20-year progress in lung cancer. He has also been a major proponent of efforts to promote tobacco control and regulation (including e-cigarettes), authoring multiple policy statements and leading frequent Capitol Hill briefings, Dr. Herbst has authored or co-authored more than 300 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has appeared in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, and the New England Journal of Medicine. Work published in Nature was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum. Dr. Herbst was a member of the National Cancer Policy Forum, for which he organized an IOM meeting focused on policy issues in personalized medicine. He is a member of the American Association of Cancer Research, where he chairs the Tobacco Task Force, as well as the American Society of Clinical Oncology. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. He is vice chair for developmental therapeutics for Southwestern Oncology Group’s (SWOG) Lung Committee. In 2015, his team at Yale was awarded a Lung Cancer SPORE by the NCI, and he serves as a principal investigator for a AACR/ Stand Up to Cancer Dream Team grant. For his lifetime achievement in scientific contributions to thoracic cancer research, Dr. Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the International Association for the Study of Lung Cancer at IASLC 17th World Conference on Lung Cancer in Vienna, Austria. 

Martin Reck

Martin Reck

Head of Department of Thoracic Oncology, LungenClinic Grosshansdorf
Grosshansdorf, Germany

Martin Reck, MD, PhD, is head of the Department of Thoracic Oncology and head of the Clinical Trial Department in the Department of Thoracic Oncology at the Lung Clinic Grosshansdorf, Germany. He is also Principal Investigator in the Airway Research Center North (ARCN), which is a member of the German Centre for Lung Research (DZL). Dr Reck underwent medical training at the University of Hamburg, Germany, from 1986–1993. He completed his doctorate at the General Hospital Wandsbek, Hamburg, in 1995, and received post-graduate training at the Hospital Grosshansdorf. Dr Reck was appointed as a specialist in internal medicine in 2001 and as a specialist in pulmonology in 2002. In 2008, he was awarded a post-doctoral lecturing qualification by the University of Schleswig-Holstein, Germany. Dr Reck has been a Principal Investigator (PI) or Co-PI in various clinical trials since 1993. His main interests are new medical treatments of thoracic malignancies as well as translational research related to predictive markers. A particular focus of his work has been attributed to the clinical development of antiangiogenic compounds like bevacizumab, nintedanib and other compounds. Recently he also has been deeply involved in several key trials with immunotherapies including ipilimumab, PD-1 and PDL-1 antibodies and other agents. As part of this activity he has been the principal investigator of the Keynote 24 trial investigating monotherapy with Pembrolizumab against platinum based chemotherapy in untreated patients with advanced PDL-1 expressing NSCLC (TPS =/> 50%) and the IMpower 150 trial investigating the combination of Atezolizumab, Bevacizumab and chemotherapy against  Bevacizumab and chemotherapy as first-line treatment. Besides the European Society of Medical Oncology (ESMO) Dr Reck is member of the International Association for the study of Lung Cancer (IASLC), the American society of Medical Oncology (ASCO), the German Working Group for Lung Cancer, the German Cancer Society (DKG) and the German Society of Pulmonology (DGP). He has published papers in numerous peer-reviewed journals and is member of the editorial board of Journal of Thoracic Oncology, Annals of Oncology and Lung Cancer. 

WEBCAST WILL BE TRANSMITTED LIVE ON: 
• 2 June 2020, h 17:00 CEST (UTC+2)

WEBCAST WILL BE AVAILABLE ON DEMAND ON:
• 2 June 2020, h 21:00 CEST (UTC+2), for 24 hours 

CEST (Central European Summer Time) or UTC +2 (Coordinated Universal Time)
Note: Times shown are equivalent across the globe – adjust your calendars to your preferred time zone. Customers can view the webcast in its entirety at any time during these time frames.


Agenda

Agenda


5 minutes

Welcome and Introduction

F. Cappuzzo


15 minutes

Update on Immunotherapy and chemotherapy combination in 1L mNSCLC

M. Reck


15 minutes

Markers of Response (PD-L1, STK, KRAS, TMB)

R. Herbst


10 minutes

Patient Cases

M. Reck


15 minutes

Q&A and Closing Remarks

F. Cappuzzo